4.7 Article

Why did some practices not implement new antibiotic prescribing guidelines on urinary tract infection? A cohort study and survey in NHS England primary care

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 74, 期 4, 页码 1125-1132

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dky509

关键词

-

资金

  1. Health Foundation [7599]
  2. National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford
  3. NIHR School of Primary Care Research grant [327]

向作者/读者索取更多资源

Objectives To describe trends and geographical variation in prescribing of trimethoprim and nitrofurantoin to treat urinary tract infections, to describe variation in implementing guideline change and to compare actions taken to reduce trimethoprim use in high- and low-using Clinical Commissioning Groups (CCGs). Methods A retrospective cohort study and interrupted time series analysis of English NHS primary care prescribing data, complemented by information obtained through Freedom of Information Act requests to CCGs. The main outcome measures were variation in practice and CCG prescribing ratios geographically and over time, including an interrupted time series, and responses to Freedom of Information requests. Results The amount of trimethoprim prescribed, as a proportion of nitrofurantoin and trimethoprim combined, remained stable and high until 2014, then fell gradually to <50% in 2017; this reduction was more rapid following the introduction of the Quality Premium'. There was substantial variation in the speed of change between CCGs. As of April 2017, for the 10 CCGs with the lowest trimethoprim ratios, 9 had reported at least one of: formulary change, work plan or incentive scheme to change prescribing behaviour. None of the 10 highest-ratio CCGs did so. Conclusions Many CCGs failed to implement an important change in antibiotic prescribing guidance, and there is strong evidence suggesting that CCGs with minimal prescribing change did little to implement the new guidance. We recommend: (i) a national programme of training and accreditation for medicines optimization pharmacists; and (ii) remedial action for CCGs that fail to implement guidancewith all materials and data shared publicly for both such activities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据